1093 — CSPC PHARMACEUTICAL Share News
0.000.00%
Last trade - 00:00- HK$96.15bn
- HK$77.27bn
- CNY26.01bn
Brief: CSPC Pharmaceutical Says FDA Approves CSPC Pharma's SYH9017 For Clinical Trials In U.S.
Brief: CSPC Pharmaceutical Says Wang Huaiyu Resigns As Executive Director
Brief: CSPC Pharmaceutical Receives $1.2 Billion Upfront Payment From Astrazeneca
Brief: CSPC Pharmaceutical Says Ennituo (Anbenitamab Injection) Got Marketing Authorisation From NMPA
Cspc Pharmaceutical Hits One: year low as quarterly profit plunges
Brief: CSPC Pharmaceutical Group Posts Q1 Net Income Attributable RMB859.8 Million
Brief: Cspc Pharmaceutical Says Ustekinumab Injection (Enyike) Receives Marketing Authorisation From NMPA
CSPC Pharmaceutical rises most in eight weeks on drug registration nod
Brief: CSPC Pharmaceutical Says Budesonide Enteric-Coated Capsules Obtain Drug Registration Approval From NMPA China
Brief: CSPC Pharmaceutical Says SYH2095 Tablets Obtain Clinical Trial Approval In China
Brief: CSPC Pharmaceutical Posts Q1 Net Loss Attributable RMB 93.9 Million For CSPC Innovation Pharmaceutical
Brief: CSPC Pharmaceutical Says Phase III Study Of Anbenitamab With Docetaxel Meets Primary Endpoint
Brief: CSPC Pharmaceutical Logs FY Net Income Attributable RMB 3,882.1 Mln
Brief: CSPC Pharmaceutical Aprepitant Injection (4.4Ml32Mg) Obtains Drug Registration Approval In China
Brief: Cspc Pharmaceutical Says GLP-1/GIP Receptor Dual-Biased Agonist Polypeptide Injection Obtains Clinical Trial Approval In China
Brief: CSPC Pharmaceutical Says FY Net Loss Attributable For CSPC Innovation Pharmaceutical Of RMB241.1 MLN
Brief: Cspc Pharmaceutical Says Syh2059 Powder Gets Clinical Trial Approval In China, U.S.
Brief: CSPC Pharmaceutical Says PDE4B Inhibitor Obtains U.S. Clinical Trial Approval
Brief: CSPC Pharmaceutical Says Indacaterol Acetate And Mometasone Furoate Powder For Inhalation Obtains Clinical Trial Approval In China